Delivery Order SPE2DB20D9331-SPE2DB25FL1Q5
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8.3k by the Defense Logistics Agency on August 21, 2025, for the supply of Xtandi 80 mg tablets (60-count). This firm fixed-price delivery order, with an ultimate completion date of August 22, 2025, represents a direct fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The award carries no...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,955.39 by the Defense Logistics Agency on July 23, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was issued without a set-aside designation, allowing the vendor to compete on an unrestricted basis. The award represents a continuation...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 80 mg tablets (60-count units) with a ceiling value of $4,169.59. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 14, 2025, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $4,169.59. This firm fixed-price delivery order carries an ultimate completion date of July 15, 2025, and represents part of the company's ongoing pharmaceutical supply relationship with the Defense Logistics Agency (DLA) Medical Supply Chain division....
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 16, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract employs firm fixed-price pricing and carries an ultimate completion date of July 17, 2025. This delivery order was awarded without a set-aside designation, allowing the vendor to compete directly in the federal...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on August 5, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract utilizes a firm fixed-price delivery order mechanism without a set-aside designation, with an ultimate completion date of August 6, 2025. This award represents a single delivery order executed under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 14, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, which is expected to be completed by July 15, 2025, represents a discrete fulfillment under the company's larger Indefinite Delivery Contract with DLA. The award carries no set-aside...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB25FL1Q5Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The award carries no set-aside designation, allowing the vendor to compete on an open basis despite its woman-owned small business status. Xtandi is a prescription oncology medication, reflecting the company's established role in supplying specialized pharmaceutical products to military and federal healthcare facilities. This delivery order is issued under DMS Pharmaceutical Group's significant single-award IDC with the Defense Logistics Agency's SPE2DB program, valued at $499,999,999 and valid through November 2026. This overarching contract enables the DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical supplies supporting medical needs across Department of Defense healthcare sites worldwide. The contract encompasses an extensive portfolio including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, positioning DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical supply chain serving military health facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 7/28/25 |